Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mahan Moshir

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|November 17, 2007
Highly efficient peptide separations in proteomics Part 1. Unidimensional high performance liquid chromatographyKoen Sandra, Mahan Moshir, Filip D'hondt, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|March 20, 2009
Highly efficient peptide separations in proteomics. Part 2: bi- and multidimensional liquid-based separation techniquesKoen Sandra, Mahan Moshir, Filip D'hondt, et al.
Muscle & Nerve|July 2, 2026
Optimization of the Cell-Based Assay Methodology to Study Degradation of Acetylcholine Receptors (Antigenic Modulation) by Antibodies From Myasthenia Gravis PatientsPeng Du, Marina Mané-Damas, Fien M Verhamme, et al.
Mabs|October 19, 2013
A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivoJohannes Trebing, Isabell Lang, Martin Chopra, et al.
Journal of Immunotoxicology|February 13, 2025
Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeysOrnella Binazon, Mario Cocco, Daniel Thwaites, et al.
Mabs|February 5, 2014
ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockadeKaren Silence, Torsten Dreier, Mahan Moshir, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 4, 2026
Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimodFatemeh Khani-Habibabadi, Fien M Verhamme, Mahan Moshir, et al.
Human Vaccines & Immunotherapeutics|March 3, 2025
Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination modelsPrajakta Warang, Gagandeep Singh, Mahan Moshir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced MalignanciesPhilippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
Nature Medicine|July 1, 2020
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agentsCarsten Riether, Thomas Pabst, Sabine Höpner, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|November 17, 2007
Highly efficient peptide separations in proteomics Part 1. Unidimensional high performance liquid chromatographyKoen Sandra, Mahan Moshir, Filip D'hondt, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|March 20, 2009
Highly efficient peptide separations in proteomics. Part 2: bi- and multidimensional liquid-based separation techniquesKoen Sandra, Mahan Moshir, Filip D'hondt, et al.
Muscle & Nerve|July 2, 2026
Optimization of the Cell-Based Assay Methodology to Study Degradation of Acetylcholine Receptors (Antigenic Modulation) by Antibodies From Myasthenia Gravis PatientsPeng Du, Marina Mané-Damas, Fien M Verhamme, et al.
Mabs|October 19, 2013
A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivoJohannes Trebing, Isabell Lang, Martin Chopra, et al.
Journal of Immunotoxicology|February 13, 2025
Effects of efgartigimod treatment on humoral and cellular immune responses: analysis of T-cell-dependent antibody response in cynomolgus monkeysOrnella Binazon, Mario Cocco, Daniel Thwaites, et al.
Mabs|February 5, 2014
ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockadeKaren Silence, Torsten Dreier, Mahan Moshir, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 4, 2026
Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimodFatemeh Khani-Habibabadi, Fien M Verhamme, Mahan Moshir, et al.
Human Vaccines & Immunotherapeutics|March 3, 2025
Impact of FcRn antagonism on vaccine-induced protective immune responses against viral challenge in COVID-19 and influenza mouse vaccination modelsPrajakta Warang, Gagandeep Singh, Mahan Moshir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced MalignanciesPhilippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
Nature Medicine|July 1, 2020
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agentsCarsten Riether, Thomas Pabst, Sabine Höpner, et al.
Pageof 2